Monotherapy response rates for inhibitors of programmed cell death protein-1 or its ligand (anti-PD-1/L1) across solid tumors are generally modest at approximately 20–30%, and much lower in some tumor types3,4. The gene discussed is PDCD1; the disease is neoplasm.